Current pancreatic cancer antigen targets in clinical trials for CAR-T cell therapy include CEA, mesothelin, CD133, CD70, CLD18, HER2, GPC3, PSCA, EGFR variant III, and MUC-1 [242]. The gene discussed is ERBB2; the disease is pancreatic neoplasm.